BrainsWay Gains FDA Clearance for Deep TMS™ as Adjunct Therapy for Adolescents with Major Depressive Disorder

The decision is based on one of the most comprehensive real-world adolescent neuromodulation datasets ever submitted to the agency: tracking 1,120 adolescents treated across 35 U.S. TMS centers between 2012 and 2024. The dataset included both high-frequency (18 Hz) and intermittent theta-burst (iTBS) Deep TMS protocols, with outcomes showing an average 12.1-point improvement on the PHQ-9 scale after 36 sessions and a 66.1% response rate (≥50% improvement) in this population.

With this clearance, Deep TMS becomes the first and only TMS device cleared for an age range spanning 15 to 86 years in the treatment of depression—broadening the addressable market across adolescents and adults alike.

Implications for Investors

• Market expansion: The label extension into the adolescent population opens a new therapeutic segment for BrainsWay—an age-group with limited effective treatment options and growing incidence of depression.
• Competitive differentiation: Offering a non-pharmaceutical, non-invasive neuromodulation tool for teenagers places BrainsWay ahead of many alternate therapies that are drug-based or less precisely targeted.
• Commercial upside: As clinical adoption ramps for adolescent MDD, BrainsWay may capture new referral streams from pediatric, adolescent-psychiatry and TMS clinics, potentially increasing device utilization, service revenue and recurring maintenance/support income.
• Strategic validation: The clearance reinforces BrainsWay’s leadership in the neuromodulation space—underlining its device platform’s scalability and long-term potential across age ranges and indications.

Considerations & Risks

• Adjunct indication: The clearance is for “adjunct therapy”—meaning Deep TMS is intended to supplement, not replace, existing treatments. Investing should account for the need to integrate with clinical workflows and insurance reimbursement.
• Reimbursement & adoption: Success depends on insurance payor coverage, clinician acceptance, referral patterns and patient access. These dynamics often take years to mature in device markets.
• Commercial execution: The clinical data are strong, but translating regulatory clearance into revenue growth demands marketing, training, reimbursement infrastructure and service support—all of which entail risk and investment.
• Device market dynamics: TMS is one segment of a broader behavioral-health market. Competitive pressures from other modalities (including drug, digital therapeutics and neuromodulation) remain real.

Bottom Line

BrainsWay’s FDA clearance of Deep TMS for adolescents aged 15–21 marks a meaningful inflection point. The move significantly expands the eligible patient population, strengthens the company’s competitive position in neuromodulation, and potentially opens a new growth channel. While the commercial impact will unfold over time—and hinges on adoption and reimbursement—a clear regulatory milestone has been achieved. Investors may now watch for field uptake, contract wins, insurance coverage developments and the company’s ability to convert this advance into sustainable growth.